Comparative Study About Different Doses of Remimazolam in Short Laparoscopic Surgery: A Randomized Controlled Double-Blind Trial
Li Luo,Jiduan Jiang,Min Zhang,Zhiqiang Guo,Xianzheng Zhang,Fenglin Wang,Fan Yang
DOI: https://doi.org/10.2147/tcrm.s428278
2023-10-21
Therapeutics and Clinical Risk Management
Abstract:Li Luo, 1 Jiduan Jiang, 2 Min Zhang, 1 Zhiqiang Guo, 1 Xianzheng Zhang, 1 Fenglin Wang, 1 Fan Yang 1 1 Department of Anesthesiology, Suining Central Hospital, Suining City, Sichuan Province, People's Republic of China; 2 Department of Anesthesiology, Suining First People's Hospital, Suining City, Sichuan Province, People's Republic of China Correspondence: Fan Yang, Department of Anesthesiology, Suining Central Hospital, Suining City, Sichuan Province, 629000, People's Republic of China, Email Objective: To study the efficacy and safety of different doses of remimazolam used for induction and maintenance in short laparoscopic surgery. Methods: A randomized controlled trial was conducted between May 2021 and May 2022 on patients underwent laparoscopic surgery for 30 minutes to an hour. Based on the drug used and the infusion rate, included patients were allocated into the Low-group of remimazolam (using a constant infusion rate of 6.0 mg/kg/h for induction and the rate of 1 mg/kg/h for maintenance), the Median-group (9.0 mg/kg/h for induction, 2 mg/kg/h for maintenance), the High-group (12.0 mg/kg/h for induction, 3.0 mg/kg/h for maintenance), and the Propofol group. The postoperative extubation time was used as the primary outcome. Results: A total of 192 patients were included in the study, with 47, 48, 48, and 49 patients in the Low-, Median-, High-, and Propofol group, respectively. There was a significant difference in postoperative extubation time, with the High-group having the highest duration of 15.21± 2.34 minutes compared to the Median-group (13.17± 1.71 minutes, p < 0.001), Low- group (12.72± 1.31 minutes, p < 0.001), and the Propofol group (12.24± 1.23 minutes, p < 0.001). No significant difference was found between the Low-group and the Propofol group, while the Median-group still showed higher postoperative extubation time compared to the Propofol group ( p =0.008). Conclusion: Compared to propofol, total intravenous induction and maintenance with high and median dosages of remimazolam may prolong postoperative extubation time. Remimazolam can be safely used for induction and maintenance at various doses while not increasing the likelihood of adverse events. Keywords: remimazolam, propofol, general anesthesia, extubation time, laparoscopic surgery Remimazolam, a new ultrashort benzodiazepine, acts through gamma-aminobutyric acid-a (GABA-A) receptors at the amygdala and reticulum activating system binding sites. 1 By altering the conformation of chloride channels, it inhibits the action of these channels in the central nervous system and causes hyperpolarization. 2 Midazolam, a traditional benzodiazepine used for sedation and anticonvulsants since 1982, has some drawbacks that limit its use for the maintenance of general anesthesia, including drug accumulation and prolonged sedation. 3 Remimazolam, on the other hand, is a midazolam derivative with an ester moiety added and two forms - besylate and tosylate. 4 Non-specific tissue esterases metabolize it, with its main metabolite CNS7054 possessing reduced binding capacity with the GABA-A receptor. 4 Reports indicate that remimazolam has the advantages of rapid onset of action, short recovery time, and stable hemodynamics. 4 Furthermore, flumazenil can quickly and specifically reverse its sedative effects, making it increasingly used for clinical anesthesia. 5 Remimazolam was first approved for procedural sedation during gastrointestinal endoscopy. 4 It was only recently approved in November 2021 for inducing and maintaining general anesthesia in China. Despite the package insert allowing for a 3-fold difference between the maximum and minimum dose of remimazolam for induction and maintenance doses, few studies have been conducted to compare the efficacy of different doses of remimazolam used for induction and maintenance of general anesthesia. To address this gap, this study applied different doses of remimazolam for short laparoscopic surgery and compared it with Propofol, focusing on the efficacy and safety of the different doses of remimazolam for induction and maintenance of general anesthesia, particularly in terms of anesthesia recovery and incidences of adverse event. The study recruited patients who underwent short laparoscopic surgery between May 2021 and May 2022 at Suining Central Hospital as participants. Inclusion criteria were as follows: aged between 18 and 60 years old, American Society of Anesthesiologists (ASA) grade I–II, operation time of 30 minutes to 1 hour, voluntary participation with informed consent signed by the patients and t -Abstract Truncated-
health care sciences & services